EU Medicines Marketed by Our Partners

All product information provided is intended for the European Union audience only.

These products may not be available in all Member States of the EU, or in countries outside the EU or may be available under a different trademark; in different strengths; or for different indications. Countries outside the EU may have different regulatory requirements that would call for different information to be available.

EU Medicines Made Available by Our Partners

All therapeutic information provided is intended for the European Union audience only.

These treatments may not be available in all Member States of the EU, or in countries outside the EU or may be available under a different trademark; in different strengths; or for different indications. Countries outside the EU may have different regulatory requirements that would call for different information to be available.

We have granted licenses to medicines or to technologies which enable third parties to develop, provide and, in some cases, manufacture for which we receive royalties and/or manufacturing revenues.

Such arrangements in the EU include the following:

About Nektar Therapeutics and AstraZeneca Agreement for MOVENTIG in the EU

Under our global agreement with AstraZeneca for MOVENTIG (MOVANTIK in the U.S.), AstraZeneca is responsible for all development and commercialization. We receive escalating royalties on revenue from MOVENTIG in the European Union starting in the high single digits and ranging to the low double digits. For revenue in the U.S. and rest of world, we receive escalating royalties starting at 20%. We are also eligible to receive additional tiered revenue milestone payments based upon global net revenue of MOVANTIK/MOVENTIG.
 

Nektar Therapeutics and Baxalta (a division of Shire plc) Agreement for ADYNOVATE/ADYNOVI

Under our collaboration with Baxalta, a wholly-owned subsidiary of Shire plc (formerly
Baxter), we developed ADYNOVI (marketed as ADYNOVATE in the US), an extended half-life
recombinant factor VIII (rFVIII) treatment for Hemophilia A based on
ADVATE ®  [Antihemophilic Factor (Recombinant)]. Baxalta is responsible for development
and commercialization and we supply manufacturing materials for a portion of the supply
chain to manufacture ADYNOVATE/ADYNOVI.

We receive escalating royalties of between 4-6 percent on global net revenue of
ADYNOVATE up to $1.2 billion in revenue; for revenue above $1.2 billion, we receive a flat
13 percent royalty. Nektar Therapeutics is also eligible to receive additional tiered revenue
milestone payments based upon global net revenue of ADYNOVATE/ADYNOVI.

EU Medicines Using Our Technologies

We have granted licenses to our technologies which enable third parties to develop, commercialize and, in some cases, manufacture for which we receive royalties and/or manufacturing revenues.

MOVENTIG is a trademark of the AstraZeneca group of companies. AstraZeneca‘s partner, Kyowa Kirrin, markets MOVENTIG in the EU.